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Previous in vitro and case–control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder
cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer
types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been
studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall
bladder cancer and urothelial cell carcinoma (UCC) in a case–control study nested within the European Prospective Investigation
into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005
were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up,
time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No
association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for
highest versus lowest fourth: 0.91, 95% CI: 0.66–1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65–1.26, ptrend = 0.40).
There was no signiﬁcant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness,
sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This ﬁrst prospective study
indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.
What’s new?
Past prospective studies have shown a positive association between circulating insulin-like growth factor I (IGF-I) concentration
and colorectal, prostate, and breast cancer risk. However, the association between circulating IGF-I concentrations and bladder
cancer risk remains uncertain. Using a nested-case control study with 843 bladder cancer cases across 9 European countries,
for the ﬁrst time here the authors examined prospectively the association between pre-diagnostic circulating IGF-I
concentrations and bladder cancer risk. IGF-I was not associated with overall risk of bladder cancer or urothelial cell carcinoma.
Further prospective data, including on tumour aggressiveness, are required to examine the association in greater detail.
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Introduction
Bladder cancer is the ninth most common cancer worldwide,
with 60% of cases occurring in high-income countries.1 There
is strong evidence that older age, male sex, family history of
bladder cancer, genetic susceptibility, smoking, arsenic in
drinking water, occupational exposures to aromatic amines
and schistosomiasis infections (only in low-income countries)
are risk factors for bladder cancer.2,3 However, the role of
other possible risk factors remains unclear.4
Insulin-like growth factor I (IGF-I) is a peptide hormone
that can induce mitosis, prevent apoptosis, promote angiogen-
esis through vascular endothelial growth factor (VEG-F), and
increase cell migration.5 Autocrine IGF-I signalling from
transformed cancerous cells is common, and is an implied
mechanism for uncontrolled cell growth.6 A number of pro-
spective studies have shown a consistent positive association
between circulating IGF-I concentration and risk of certain
cancers such as colorectal, prostate and female breast7–9 can-
cer. Previous in vitro studies on human bladder cancer cell
lines have found that IGF-I confers a growth advantage to
urothelial bladder cancer cells over normal cells.10 IGF-I’s
receptor, insulin-like growth factor I receptor (IGF-IR), has
been found to be overexpressed in human bladder cancer
cells,11 and to play a role in the motility and invasion of blad-
der cancer cells.12 Evidence from a previous case–control
study has also suggested that elevated circulating IGF-I con-
centrations may be associated with higher risk of bladder can-
cer.13 However, as far as we are aware, the association
between circulating IGF-I concentrations and risk of bladder
cancer has not been studied prospectively.
The aim of this study was to investigate the association
between pre-diagnostic circulating concentrations of IGF-I
and risk of overall bladder cancer and urothelial cell carci-
noma (UCC) using a case–control study nested within the
European Prospective Investigation into Cancer and Nutrition
(EPIC) cohort.
Materials and Methods
Study population and design
EPIC is a multicentre prospective cohort study of 519,978 par-
ticipants (153,457 males and 366,521 females), mostly aged
30–75 years. Brieﬂy, subjects were recruited from 23 centres
in 10 European countries (Denmark, France, Greece, Ger-
many, Italy, Netherlands, Norway, Spain, Sweden and United
Kingdom [UK]) between 1992 and 2000. The original purpose
of the cohort was to study the relationship between dietary
intake and biomarkers (including hormones) and cancer risk.
The majority of participants were recruited from the general
population, and were invited to participate based on geo-
graphic and administrative boundaries. All EPIC study partici-
pants gave written informed consent at recruitment. Approval
for the study was granted by the Internal Review Board of the
International Agency for Research on Cancer (IARC, Lyon,
France) and from ethics committees at participating
institutions.14
At recruitment, participants provided detailed information
on dietary and non-dietary factors. Approximately 400,000
participants also gave a blood sample that was split into ali-
quots of plasma, serum, buffy coat and erythrocytes. The ali-
quots were stored in liquid nitrogen (−196C) for future
laboratory analysis at IARC, with the exception of Denmark
and Sweden, where they were stored locally (at −150C and
−70C, respectively). A more detailed description of subject
recruitment, baseline data collection and standard protocols in
the EPIC cohort has been previously reported.14
Eligibility criteria for this analysis included: (i) an available
blood sample, (ii) information available on the date of blood
collection and (iii) no history of cancer other than non-
melanoma skin cancer at recruitment.
Follow-up and selection of cases and controls
In most countries, incident bladder cancer cases were identi-
ﬁed via record linkage to national and regional cancer regis-
tries. In France, Germany and Greece, follow-up was
conducted using a variety of methods, including health insur-
ance records, cancer and pathology registries, self-reported
cancer veriﬁed with medical records, and active follow-up
through participants and relatives. Follow-up for these ana-
lyses ended between January 2002 (Germany) and October
2005 (Spain).
Cases were eligible for inclusion if they were diagnosed
with bladder cancer (International Classiﬁcation of Disease-
Oncology, Third Edition, topography code C67) between the
date of blood collection and end of follow-up. UCC was
deﬁned by morphology codes 812–813. Bladder cancer diag-
noses were further characterised by their stage and grade.
Tumours with a stage-grade combination of Ta and Grade
1–2 were considered non-aggressive, while tumours that were
T1 and higher, carcinoma in situ or Grade 3 and higher
(including Ta) were considered aggressive. A total of 1,861
cases and controls were eligible for matching, of which
150 did not have IGF-I measurement and 16 had no date of
blood collection. The 9 bladder cancer cases from Norway
were excluded from this analysis because they either failed to
meet the eligibility criteria, or because no suitable control
matches were found. The ﬁnal sample comprised 843 cases
and 843 controls. The distribution of bladder cancer cases by
EPIC countries can be found in Supporting Information
Table S1.
Each bladder cancer case was matched to one control par-
ticipant, selected at random among all cohort members alive
and without any reported cancer diagnosis (except non-
melanoma skin cancer) at date of diagnosis of the index case.
Controls were matched based on recruitment centre, sex, age
at recruitment (3 years), date of blood collection
(3 months), time of day of blood collection (2 hr) and
fasting status at blood collection (<3, 3–6, >6 hr). An
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incidence density sampling protocol was used, such that con-
trols could later become cases if they developed bladder can-
cer, and each control participant could be sampled more
than once.
Laboratory assay
Pre-diagnostic plasma IGF-I concentrations were measured
using the automated IDS-iSYS immunoassay system
(Immunodiagnostic Systems Ltd.) at the Cancer Epidemiology
Unit laboratory, University of Oxford, UK. As a quality control,
two control samples prepared from commercially available
pooled plasma (Seralab) were assayed for every 20 study partic-
ipant samples. Samples from matched case–control sets were
analysed within the same batch and laboratory technicians were
blinded to case or control status. The intra-batch coefﬁcient of
variation was 2.4%, the inter-batch coefﬁcient of variation was
3.9% and the overall coefﬁcient of variation was 4.2% at a mean
IGF-I concentration of 13.8 nmol/L. The lower limit of detec-
tion was 1.3 nmol/L, adequate to detect the lowest concentra-
tion in all study samples.
Table 1. Characteristics of 843 bladder cancer cases and 843 controls
Cases (n = 843) Controls (n = 843) p-value1
IGF-I, nmol/L 14.2 (13.9–14.4)2 14.3 (14.0–14.6)2 0.223
Sex (male), n (%) 613 (72.7%) 613 (72.7%) –
Age at blood collection, year 58.5 (7.7) 58.4 (7.7) –
Smoking status, n (%) <0.0014
Never 153 (18.1%) 329 (39.0%)
Former 303 (35.9%) 287 (34.0%)
Current (15 cigarettes/day, other5) 227 (26.9%) 154 (18.3%)
Current (15+ cigarettes/day) 148 (17.6%) 59 (7.0%)
Unknown 12 (1.4%) 14 (1.7%)
Physical activity, n (%) 0.834
Inactive 221 (26.2%) 207 (24.6%)
Moderately inactive 273 (32.4%) 288 (34.2%)
Moderately active 174 (20.6%) 170 (20.2%)
Active 164 (19.5%) 170 (20.2%)
Unknown 11 (1.3%) 8 (0.9%)
Education, n (%) 0.634
<Secondary 584 (69.3%) 570 (67.6%)
Secondary 94 (11.2%) 87 (10.3%)
Degree 139 (16.5%) 158 (18.7%)
Unknown 26 (3.1%) 28 (3.3%)
Body mass index, kg/m2 26.7 (4.0) 26.5 (3.8) 0.19
Total energy intake, kcal/day 2,288 (415) 2,293 (434) 0.82
Alcohol intake, mL/day 19.0 (23.3) 17.1 (21.0) 0.253
Cases only
Age at diagnosis, year 63.6 (8.1) –
Time between blood collection and diagnosis, year 5.1 (2.8) –
Tumour aggressiveness, n (%)
Non-aggressive 344 (40.8%) –
Aggressive 392 (46.5%) –
Unknown 107 (12.7%) –
Urothelial cell carcinoma, n (%) 766 (92.1%) –
Table summarising the main baseline characteristics of the study participants. All values are means (standard deviation) for continuous variables, or
n (%) when indicated.
1All values are two-sided p-value for paired t-test unless otherwise specified.
2Geometric mean (95% Confidence Interval).
3p-value for non-parametric Wilcoxon rank sum test for non-normally distributed variables.
4p-value for chi-square test of association.
5Other forms of tobacco such as cigars and occasional smokers.
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Statistical analysis
Baseline characteristics were summarised by their mean and
standard deviation, or geometric mean for IGF-I concentra-
tion. Differences in baseline characteristics between cases and
control subjects were tested by paired t-test or Wilcoxon’s
rank sum test for continuous variables, depending on the nor-
mality of the distribution. A chi-square test was used for cate-
gorical variables.
For all analyses, circulating IGF-I concentrations were log
transformed to approximate normality. Conditional logistic
regression models were used to calculate the odds ratios
(ORs) and 95% conﬁdence intervals (CIs) for risk of incident
bladder cancer by fourths of circulating IGF-I concentration,
with the lowest fourth as the reference category. All analyses
were conditioned on the previously described matching
variables.
In the adjusted model, only smoking status, which
included intensity (never; former; current: ≤15 cigarettes/day,
occasional or cigar smoker; current: >15 cigarettes/day and
unknown), was included as a covariate. The following vari-
ables were identiﬁed a priori from the literature2 and tested as
potential confounders, but did not contribute signiﬁcantly to
model parameters according to likelihood ratio tests (LRTs),
and were therefore excluded from the ﬁnal model: alcohol
consumption, total ﬂuid intake, body mass index (BMI), edu-
cation, physical activity and diabetes. The linear trend for the
association of IGF-I with bladder cancer risk was derived from
regression models using the median concentrations within
fourths as a continuous variable. The fully-adjusted ﬁnal
model was also run with a continuous, standardised version of
the log IGF-I variable to determine the risk of bladder cancer
per standard deviation (SD) increase in circulating IGF-I
concentration.
To examine possible differences in disease aetiology, a sen-
sitivity analysis was conducted on UCC only, which accounts
for the majority of bladder cancer cases.1 We also conducted a
further sensitivity analysis restricting the model to participants
with known smoking status. Subgroup analyses were con-
ducted on subgroups deﬁned a priori: sex (male vs. female),
smoking status (never vs. ever), and time from blood collec-
tion to diagnosis (<4 vs. ≥4 years). To test for heterogeneity,
we used LRTs to compare models with and without the
Table 2. Odds ratios for bladder cancer risk by fourths of IGF-I concentration
Fourths of IGF-I
Model 1 (reference) 2 3 4 ptrend
1 phet
2
All bladder cancer cases –
Cases/controls, n 220/202 221/200 199/223 203/218
OR (95% CI) 1.00 (ref ) 0.99 (0.76–1.30) 0.81 (0.62–1.07) 0.83 (0.62–1.11) 0.10
Adjusted OR (95% CI)3 1.00 (ref ) 0.99 (0.75–1.34) 0.88 (0.66–1.19) 0.91 (0.66–1.24) 0.40
Urothelial cell carcinoma only4
Cases/controls, n 199/202 208/200 181/223 188/218
OR (95% CI) 1.00 (ref ) 0.98 (0.74–1.30) 0.81 (0.60–1.08) 0.82 (0.61–1.12) 0.11
Adjusted OR (95% CI)3 1.00 (ref ) 0.99 (0.73–1.34) 0.86 (0.63–1.18) 0.91 (0.65–1.26) 0.40
By tumour aggressiveness
Non-aggressive5
Cases/controls, n 85/85 85/85 83/83 91/91
OR (95% CI) 1.00 (ref ) 1.05 (0.79–1.40) 0.89 (0.66–1.19) 0.82 (0.60–1.12) 0.11
Adjusted OR (95% CI)3 1.00 (ref ) 0.82 (0.51–1.31) 0.66 (0.41–1.06) 0.92 (0.55–1.54) 0.40
Aggressive6
Cases/controls, n 103/103 112/112 96/96 81/81
OR (95% CI) 1.00 (ref ) 1.23 (0.79–1.90) 1.36 (0.86–2.16) 0.86 (0.53–1.40) 0.34
Adjusted OR (95% CI)3 1.00 (ref ) 1.24 (0.81–1.89) 1.33 (0.85–2.09) 0.86 (0.54–1.39) 0.62 0.06
Odds ratios and 95% confidence intervals for the risk of bladder cancer by fourths of IGF-I in unadjusted and fully adjusted models. For all analyses,
bladder cancer cases and controls were matched on recruitment centre, sex, age at recruitment (3 years), date of blood collection (3 months), time
of day at blood collection (2 hr) and fasting status at blood collection (<3, 3–6, >6 hr).
1p-trend is for a test of linear trend in ORs, derived from regression models using the median concentrations within fourths of log (IGF-I) as a continu-
ous variable.
2p-heterogeneity of the adjusted model, calculated using likelihood ratio test comparing models with and without the interaction term.
3Adjusted model is adjusted for smoking status (never, former, current: 15 cigarettes/day, current: >15 cigarettes/day, unknown) and conditioned on
the matching variables (above).
4Urothelial cell carcinoma, defined as ICD-Oncology, 3rd edition topography code 67 and morphology codes 812–813.
5Non-aggressive tumour defined as Stage Ta and Grade 1–2.
6Aggressive tumour defined as Stage T1 or carcinoma in situ or Grade 3
Abbreviations: IGF-I, insulin-like growth factor I; UCC, urothelial cell carcinoma.
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interaction term between IGF-I and the subgroup variable.
For tests of heterogeneity of risk by bladder tumour aggres-
siveness (non-aggressive vs. aggressive), the control in each
matched set was assigned the characteristics of their case and
the analysis was conducted as described for the subgroups.
All analyses were conducted using Stata statistical software,
version 14.1 (Stata Corporation, College Station, TX). Two-
sided p-values are reported, with p < 0.05 considered statisti-
cally signiﬁcant.
Results
The baseline characteristics of the 843 bladder cancer cases
and 843 controls are shown in Table 1. Participants were fol-
lowed up for an average of 5.1 years. The average age at blood
collection for both controls and cases was 58 years. For cases,
the average age of ﬁrst bladder cancer diagnosis was 63.6 years.
Circulating IGF-I concentrations did not differ signiﬁcantly
between cases and controls (p = 0.2), while smoking history
did (p < 0.001).
The ORs for overall bladder cancer risk, UCC only and
bladder cancer subdivided by aggressiveness by fourths of log
IGF-I, with and without adjustment for smoking status, are
shown in Table 2. No association was found between IGF-I
and overall bladder cancer risk (adjusted OR comparing the
highest fourth to the lowest fourth of concentration = 0.91,
95% CI: 0.66–1.24, ptrend = 0.40). When IGF-I was analysed as
a continuous variable, the association between circulating con-
centrations of IGF-I and bladder cancer risk remained non-
signiﬁcant (OR1SD = 0.97; 95% CI: 0.87–1.08; ptrend = 0.60).
The ORs were similar when the analyses were restricted to
UCC only (0.91, 0.65–1.26, ptrend = 0.40) and when analyses
were restricted to participants with known smoking status
(Tables 2 and 3). There was no association with risk for either
aggressive or non-aggressive cancers, and no signiﬁcant het-
erogeneity by tumour aggressiveness (pheterogeneity = 0.06)
(Table 2).
Finally, there was no evidence of heterogeneity in the
association of IGF-I and risk of overall bladder cancer by sex
Table 3. Odds ratios for bladder cancer by fourths of IGF-I concentration in subgroup and sensitivity analyses
Adjusted ORs (95% CI) by fourths of IGF-I
Model 1 (reference) 2 3 4 ptrend
1 pheterogeneity
2
By sex
Men Cases/controls, n 147/135 165/138 157/169 144/171
Adjusted OR (95% CI) 1.00 (ref ) 1.11 (0.78–1.58) 0.97 (0.68–1.37) 0.84 (0.57–1.22) 0.24
Women Cases/controls, n 73/67 56/62 42/54 59/47
Adjusted OR (95% CI) 1.00 (ref ) 0.77 (0.46–1.29) 0.67 (0.37–1.20) 1.24 (0.68–2.28) 0.78 0.10
By smoking status
Never Cases/controls, n 42/76 34/86 41/89 48/91
OR (95% CI)3 1.00 (ref ) 0.69 (0.39–1.21) 0.92 (0.52–1.66) 1.10 (0.62–1.95) 0.99
Ever Cases/controls, n 175/120 182/110 152/133 152/121
OR (95% CI)3 1.00 (ref ) 1.10 (0.77–1.56) 0.82 (0.58–1.15) 0.83 (0.57–1.20) 0.08 0.13
By time between blood collection and diagnosis
<4 years since
blood
collection
Cases/controls, n 73/77 88/80 77/74 78/85
Adjusted OR (95% CI) 1.00 (ref ) 1.08 (0.67–1.76) 1.09 (0.64–1.85) 0.97 (0.57–1.65) 0.93
4 years since
blood
collection
Cases/controls, n 147/125 133/120 122/149 125/133
Adjusted OR (95% CI) 1.00 (ref ) 0.96 (0.67–1.39) 0.80 (0.56–1.14) 0.89 (0.60–1.33) 0.35 0.79
Restricted to
participants
with known
smoking
status
Cases/controls, n 216/195 215/196 189/219 198/208
Adjusted OR (95% CI) 1.00 (ref ) 0.97 (0.75–1.31) 0.83 (0.61–1.12) 0.93 (0.67–1.28) 0.41
Adjusted odds ratios for smoking status (never, former, current: 15 cigarettes/day, current: >15 cigarettes/day, unknown) and conditioned on recruit-
ment centre, sex, age at recruitment (3 years), date of blood collection (3 months), time of day at blood collection (2 hr) and fasting status at
blood collection (<3, 3–6, >6 hr).
1p-trend is for a test of linear trend in ORs, derived from regression models using the median concentrations within fourths of log (IGF-I) as a continu-
ous variable.
2p-heterogeneity of adjusted model calculated using likelihood ratio test comparing models with and without the interaction term.
3ORs and p-heterogeneity calculated using unadjusted model to avoid collinearity by smoking status.
Abbreviations: IGF-I, insulin-like growth factor-I.
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(pheterogeneity = 0.10), smoking status (pheterogeneity = 0.13) or
time between blood collection and diagnosis (pheterogeneity=
0.79) (Table 3).
Discussion
The results from this nested case–control study across nine
European countries do not suggest an association between pre-
diagnostic circulating concentrations of IGF-I and risk for blad-
der cancer. To the best of our knowledge, this is the ﬁrst pro-
spective investigation into the association between pre-diagnostic
circulating concentrations of IGF-I and bladder cancer risk.
Previous evidence on the association between IGF-I and
bladder cancer comes from in vitro and small case–control
human studies. A case–control study of 154 US patients con-
ducted by Zhao et al. in 2003 found patients in the highest
fourth of IGF-I concentration were at increased risk for blad-
der cancer.13 A smaller case–control study by Shariat
et al. including 51 US bladder cancer patients and another
case–control conducted by Mahmoud et al. with 51 Egyptian
bladder cancer patients found no association between IGF-I
levels and bladder cancer.15,16 In case–control studies, circulat-
ing IGF-I levels could reﬂect tumour metabolism rather than
a factor inﬂuencing risk of developing the disease, since auto-
crine signalling from tumour cells could elevate IGF-I levels.5
Bladder cancer is a heterogeneous disease. The majority of
cases are of the UCC subtype, followed by the squamous cell
carcinoma subtype, with different aetiologies.2,17 In our sensi-
tivity analysis on UCC only, the OR estimates remained
unchanged from the full model, which is unsurprising given
that most cases were UCC. Bladder cancer cases can be further
divided into non-aggressive and aggressive tumours, which
have been hypothesised to be two separate diseases with distinct
molecular signatures.18 We found no association with either
aggressive or non-aggressive cancers and no signiﬁcant hetero-
geneity in the association by tumour aggressiveness. While
genetic studies have suggested that bladder cancer can be classi-
ﬁed into more speciﬁc molecular subtypes,19 we were not able
to examine this due to lack of data on tumour genotype.
The strength of this study was the use of prospectively
recorded data, which limited any impact of reverse causality on
our results. No heterogeneity was observed by time between
blood collection and diagnosis, further reducing the possibility
of reverse causality. Moreover, a moderately large sample size
allowed us to make reasonably precise estimates of the relation-
ship between circulating IGF-I concentrations and bladder can-
cer, while information on tumour subtypes enabled us to
explore possible heterogeneity in bladder cancer risk by tumour
aggressiveness. Finally, the distribution of circulating IGF-I
concentrations among controls in this study was similar to that
observed in previous prospective studies.20,21
This study has some limitations. First, the analysis relied
on a single measurement of circulating IGF-I in each partici-
pant. However, several studies with repeat samples collected
between 1 and 5 years apart have seen a moderately high tem-
poral reproducibility of IGF-I with correlations of
0.7–0.9.22–24 Therefore, although our analyses may have been
affected by regression dilution bias,25 this is unlikely to
explain the lack of an association. Second, as we did not have
information on occupational exposures for the majority of
cases and controls, we could not adjust for exposure to indus-
trial chemicals. Third, there were small numbers of cases in
subgroups deﬁned by sex, smoking status and tumour aggres-
siveness, leading to limited statistical power in these analyses.
Finally, we were unable to examine data on other IGFs or
IGF-binding proteins, which may interact with and modify
the effect of IGF-I.
In conclusion, there was no evidence of an association
between pre-diagnostic circulating IGF-I concentrations and
bladder cancer risk in the EPIC cohort. To further elucidate
the association between circulating IGF-I concentrations and
bladder cancer risk, more data from both prospective and
Mendelian randomisation studies are needed, preferably with
data on tumour subtypes and aggressiveness to compare study
results and ultimately conduct pooled analysis with a larger
sample size.
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